275 related articles for article (PubMed ID: 21376417)
21. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Horton ES; Foley JE; Shen SG; Baron MA
Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
[TBL] [Abstract][Full Text] [Related]
24. Effects of acarbose and siglitine on blood glucose fluctuation and islet β-cell function in patients with type 2 diabetes mellitus.
Wang RR; Lv ZM; Dan YP; Chen KY; Zhang C
J Biol Regul Homeost Agents; 2019; 33(2):365-374. PubMed ID: 30972995
[TBL] [Abstract][Full Text] [Related]
25. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
26. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
27. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Bellomo Damato A; Stefanelli G; Laviola L; Giorgino R; Giorgino F
Diabet Med; 2011 May; 28(5):560-6. PubMed ID: 21204958
[TBL] [Abstract][Full Text] [Related]
28. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
Raz I; Wilson PW; Strojek K; Kowalska I; Bozikov V; Gitt AK; Jermendy G; Campaigne BN; Kerr L; Milicevic Z; Jacober SJ
Diabetes Care; 2009 Mar; 32(3):381-6. PubMed ID: 19246588
[TBL] [Abstract][Full Text] [Related]
29. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
30. [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Li YX; Ding GX; Li QF; Chen L; Hu GL; Ji QH; Wang SJ; Guo Y; Luo R; Hou WK; Wang PN; Zhang NY; Zhang YP; Wang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):211-3. PubMed ID: 18505128
[TBL] [Abstract][Full Text] [Related]
31. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test.
Mori Y; Kuriyama G; Tajima N
Endocrine; 2004 Dec; 25(3):203-6. PubMed ID: 15758246
[TBL] [Abstract][Full Text] [Related]
32. Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases.
Ito S; Ogishima H; Kondo Y; Sugihara M; Hayashi T; Chino Y; Goto D; Matsumoto I; Sumida T
Mod Rheumatol; 2014 Jan; 24(1):52-9. PubMed ID: 24261759
[TBL] [Abstract][Full Text] [Related]
33. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
34. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
35. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
Hanefeld M; Schaper F; Koehler C; Bergmann S; Ugocsai P; Stelzer J; Schmitz G
Horm Metab Res; 2009 Feb; 41(2):132-6. PubMed ID: 19214923
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
[TBL] [Abstract][Full Text] [Related]
37. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
38. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
39. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes.
Morita Y; Ueno T; Sasaki N; Tateishi Y; Nagata E; Kage M; Sata M
Hepatogastroenterology; 2005; 52(65):1338-43. PubMed ID: 16201069
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
